Alley Investment Management Company LLC Buys Shares of 254,581 Kenvue Inc. (NYSE:KVUE)

Alley Investment Management Company LLC bought a new stake in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 254,581 shares of the company’s stock, valued at approximately $5,435,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in KVUE. Grove Bank & Trust raised its position in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Kenvue in the fourth quarter valued at $29,000. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the period. Fortitude Family Office LLC raised its holdings in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the 3rd quarter valued at $35,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.79 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market cap of $45.47 billion, a P/E ratio of 44.89, a P/E/G ratio of 2.62 and a beta of 1.45. The stock has a 50 day moving average of $21.50 and a two-hundred day moving average of $22.29. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.45%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analysts Set New Price Targets

Several research firms recently issued reports on KVUE. Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Piper Sandler boosted their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Canaccord Genuity Group lowered their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $23.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.